Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present BioCorRx Inc. (OTC: BICX).

Full DD Report for BICX

You must become a subscriber to view this report.


Recent News from (OTC: BICX)

BioCorRx Gains Additional Media Coverage from Fox Medical Correspondent Who Discusses the Advantages of the Naltrexone Implant
ANAHEIM, CA, April 30, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today reported that Dr. Mark Siegel, commented on the advantages of sustained relea...
Source: GlobeNewswire
Date: April, 30 2018 07:00
BioCorRx CEO Brady Granier and Actor Jeremy Miller Appear on Varney & Co. on Fox Business to Discuss the Company's Sustained Release Naltrexone Implant for Alcohol Use Disorder
ANAHEIM, CA, April 26, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, as ...
Source: GlobeNewswire
Date: April, 26 2018 08:47
BioCorRx to Participate in the First Annual Orange County Recovery Collaborative Resource Fair
ANAHEIM, CA, April 13, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company) , a developer and provider of advanced solutions in the treatment of alcohol and opioid addition, today announced that the Company will participate in the first annual Orange County Recovery C...
Source: GlobeNewswire
Date: April, 13 2018 07:18
BioCorRx to Exhibit at ASAM 49th Annual Conference in San Diego, California
ANAHEIM, CA, April 10, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company) , a developer and provider of advanced solution in the treatment of alcohol and opioid addition, today announced that the Company will have a tabletop exhibit at the American Society of Addict...
Source: GlobeNewswire
Date: April, 10 2018 07:30
BioCorRx CEO Brady Granier and Legendary Soul Man Sam Moore Appear on Fox Business Network to Discuss the Company's Naltrexone Implant, Which Helps Combat Opioid Addiction
ANAHEIM, CA, April 09, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, and lege...
Source: GlobeNewswire
Date: April, 09 2018 12:24
BioCorRx updates investors on key achievements
BioCorRx ( OTCQB:BICX ) provides a business update for the year ended December 31, 2017. Highlights for the past year: More news on: BioCorRx Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 06 2018 08:33
BioCorRx Provides Business Update for the Full Year Ended 2017
ANAHEIM, CA, April 06, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today provided a business update for the year ended December 31, 2017. Full Ye...
Source: GlobeNewswire
Date: April, 06 2018 07:30
BioCorRx Partner, Virtual Reality Medical Center, Submits Small Business Innovation Grant Application to the National Institute of Health
ANAHEIM, CA, April 05, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that its partner, Virtual Reality Medical Center (VRMC), has submitt...
Source: GlobeNewswire
Date: April, 05 2018 07:30
BioCorRx Comments on President Donald J. Trump's Initiative to Stop Opioid Abuse
ANAHEIM, CA, March 20, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today commented on President Trump’s initiative to stop opioid abuse and...
Source: GlobeNewswire
Date: March, 20 2018 10:40
SeeThruEquity Issues Update on BioCorRx Inc. (OTCQB: BICX) and Increases Price Target to $0.44
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on BioCorRx Inc. (OTCQB: BICX). The report is available here: BICX March...
Source: ACCESSWIRE IA
Date: March, 20 2018 09:25

 


About BioCorRx Inc. (OTC: BICX)

Logo for BioCorRx Inc. (OTC: BICX)

BioCorRx Inc. is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx amp reg Recovery Program, a non addictive, medication assisted treatment MAT program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one on one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long term naltrexone treatment. The Company also has an R amp amp D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.

 

 

 

Current Management

  • Brady Granier / CEO, President
  • Lourdes Felix / CFO, COO
  • Tom Welch / VP, Ops.
  • Kent Emry / Chairman, Independent Director
  • Lourdes Felix /
  • Brady Granier /

Current Share Structure

  • Market Cap: $34,431,080 - 03/16/2018
  • Authorized: 525,000,000 - 03/01/2018
  • Issue and Outstanding: 245,936,285 - 03/01/2018
  • Float: 110,031,021 - 06/27/2016

 


Recent Filings from (OTC: BICX)

All other definitive information statements
Filing Type: DEF 14CFiling Source: edgar
Filing Date: April, 10 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 05 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 02 2018
Information statements. Revised preliminary material
Filing Type: PRER14CFiling Source: edgar
Filing Date: March, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018
Preliminary proxy statement containing all other information
Filing Type: PRE 14CFiling Source: edgar
Filing Date: February, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 14 2017

 

 


Daily Technical Chart for (OTC: BICX)

Daily Technical Chart for (OTC: BICX)


Stay tuned for daily updates and more on (OTC: BICX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BICX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BICX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BICX and does not buy, sell, or trade any shares of BICX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/